查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2130838

臍帶血幹細胞市場分析與預測（至2035年）：類型、產品、服務、技術、應用、流程、部署、最終用戶、解決方案

Stem Cell Umbilical Cord Blood Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, Process, Deployment, End User, Solutions
出版日期: | 出版商: Global Insight Services | 英文 350 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

全球臍帶血幹細胞市場預計將從2025年的42億美元成長到2035年的78億美元，複合年成長率（CAGR）為6.2%。這一成長主要受再生醫學需求增加、幹細胞研究進展以及人們對臍帶血庫益處的認知不斷提高所驅動。臍帶血幹細胞市場結構較為一體化，主要組成部分包括佔市場佔有率約60%的私人臍帶血庫和占市場佔有率約40%的公共臍帶血庫。其主要應用包括再生醫學、造血幹細胞移植及遺傳疾病治療。在人們認知不斷提高和治療應用不斷進步的推動下，每年都有大量的臍帶血被儲存在市場上。

競爭格局由全球性和區域性公司共同構成，其中像臍帶血庫（Cord Blood Registry）和ViaCord這樣的公司扮演著重要角色。在新型保存和處理技術的研發方面，創新程度尤其突出。隨著公司企業發展併購和策略聯盟也日益頻繁。近期趨勢表明，各公司正致力於提昇技術能力和擴展生物檢體資料庫網路，以鞏固其市場地位。

市場區隔
類型 同種植物，自家種植，其他品種
產品 臍帶血單位、臍帶組織單位、其他
服務 收穫、運輸、加工、保藏及其他
科技 冷凍保存、細胞增生、細胞分離及其他
目的 癌症治療、血液疾病、代謝失調、免疫系統疾病、再生醫學等。
流程 收集、處理、保存及其他
發展 公共銀行、私人銀行、混合銀行及其他
最終用戶 醫院、研究機構、生物樣本庫及其他
解決方案 治療方案、研究方案及其他

臍帶血幹細胞市場的「類型」細分市場主要受異體和自體幹細胞療法優勢的驅動。異體幹細胞治療使用來自捐贈者的細胞，因其可用於治療多種血液系統疾病而廣泛應用。自體療法使用患者自身的細胞，因其免疫排斥風險較低而備受關注。遺傳性疾病盛行率的不斷上升和個人化醫療的進步是推動該細分市場需求的主要因素。

此技術領域的核心是冷凍保存和細胞增殖技術。冷凍保存仍然是確保幹細胞長期存活以用於未來治療應用的基礎技術。細胞增殖技術日益重要，因為它們能夠生產出治療所需的足夠數量的細胞。生物反應器設計和自動化方面的創新正在提高這些技術的效率和擴充性，從而滿足日益成長的再生醫學應用需求。

在應用領域，血液系統疾病和癌症的治療是推動市場成長的主要動力，其中幹細胞移植在這些領域的高成功率是關鍵因素。臍帶血幹細胞在白血病、淋巴瘤和鐮狀細胞貧血的治療中已被廣泛應用，並促進了該領域的成長。再生醫學領域的新興應用，例如神經病學和心臟病學，在持續的臨床試驗和研究舉措的推動下，正在拓展市場範圍。

在終端使用者領域，醫院和專科診所作為幹細胞移植和治療的主要施行地點，發揮主導作用。這些機構利用其完善的基礎設施和處理複雜手術的專業技術。臍帶血庫也發揮著至關重要的作用，提供儲存和管理服務，支持臨床和研究活動。隨著醫院和研究機構之間合作的不斷深入，創新得以促進，先進幹細胞療法的應用範圍也不斷擴大。

「組件」部門專注於臍帶血保存和處理所需的關鍵產品和服務。隨著越來越多的父母選擇保存子女的臍帶血以備將來使用，對保存服務（尤其是私人臍帶血庫）的需求日益成長。處理服務對於確保保存的幹細胞的品質和活性至關重要。先進的IT解決方案和自動化處理系統的整合正在提高營運效率和可靠性，從而推動該部門的成長。

區域概覽

北美：北美臍帶血幹細胞市場高度成熟，這得歸功於先進的醫療基礎設施和大量的研發投入。美國是主要市場，其成長動力主要來自生物技術和再生醫學領域的需求。加拿大也透過政府支持政策和不斷提高的公眾意識，為市場成長做出了貢獻。

歐洲：歐洲市場已趨於成熟，醫療保健和製藥業的需求強勁。英國和德國是值得關注的國家，它們受益於健全的醫療保健體系和持續的研究舉措。歐盟的法規結構也促進了市場擴張。

亞太地區：亞太地區正經歷快速成長，市場日趨成熟，這主要得益於醫療保健服務的普及和公眾意識的提高。中國和日本是生物技術和再生醫學領域投資最強大的國家。各國政府為促進醫療保健進步而採取的措施也進一步推動了市場需求。

拉丁美洲：拉丁美洲市場尚處於發展初期，但已引起醫療保健產業的廣泛關注。巴西和墨西哥是值得關注的市場，這得益於醫療基礎設施的不斷改進以及公眾對幹細胞療法認知度的提高。然而，經濟挑戰可能會影響其成長速度。

中東和非洲：中東和非洲地區仍是一個新興市場，其成長主要由醫療保健和生物技術產業驅動。阿拉伯聯合大公國和南非是關鍵國家，受益於政府對醫療基礎設施投資和醫學研究的支持。然而，資源匱乏和認知度不足限制了市場擴張。

主要趨勢和促進因素

趨勢一：幹細胞處理技術的進步

由於幹細胞處理和儲存技術的進步，臍帶血幹細胞市場正經歷快速成長。自動化處理系統和冷凍保存技術等創新提高了幹細胞庫的效率和可用性。這些技術提高了細胞回收率，並更好地維持了細胞活性，使臍帶血成為再生醫學應用中更可靠的來源。因此，這些技術進步正在推動臍帶血庫服務的全球擴張。

趨勢二：監理支援與標準化

隨著全球監管機構日益認可幹細胞療法的潛力，臍帶血市場正朝著更完善的框架和標準化方向發展。美國食品藥物管理局（FDA）和歐洲藥品管理局（EMA）等機構制定的採集、處理和儲存指南，正在增強市場信心，並刺激該領域的投資。標準化確保了品質和安全，這對於獲得公眾和專業人士的認可，並最終推動市場成長至關重要。

三大趨勢：意識與接受度提高

孕婦和醫護人員對臍帶血庫益處的認知正在不斷提高。宣傳活動和媒體報告的增加，使人們更加關注臍帶血庫在治療包括白血病和遺傳性疾病在內的多種疾病方面的潛力。這種日益成長的認知促使越來越多的家庭將臍帶血庫作為一種寶貴的「生物保險」，以應對未來的醫療需求，註冊用戶數量也在增加。

趨勢（4個標題）：治療應用的擴展

臍帶血治療應用範圍的不斷擴大是推動市場成長要素。研究和臨床試驗不斷發現幹細胞在治療包括自體免疫和神經系統疾病在內的多種疾病方面的新用途。隨著治療領域的拓展，製藥公司的投資和關注度日益提高，進一步加速了市場成長和創新。

五大趨勢：策略聯盟與夥伴關係

臍帶血庫、研究機構和生技公司之間的策略聯盟和夥伴關係正在推動創新和市場擴張。這些合作促進了知識、資源和技術的共用，加速了新療法的發展並提高了服務品質。此類夥伴關係對於克服成本、擴充性和監管合規性的挑戰至關重要，最終推動了臍帶血幹細胞市場的成長。

目錄

第1章摘要整理

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制因素
  • 複合年均成長率分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章：細分市場分析

  • 市場規模及預測：依類型
    • 同種
    • 自有住房
    • 其他
  • 市場規模及預測：依產品分類
    • 臍帶血單位
    • 臍帶組織單位
    • 其他
  • 市場規模及預測：依服務分類
    • 收集/運輸
    • 加工
    • 保持
    • 其他
  • 市場規模及預測：依技術分類
    • 冷凍保存
    • 細胞增殖
    • 細胞分離
    • 其他
  • 市場規模及預測：依應用領域分類
    • 癌症治療
    • 血液疾病
    • 代謝性疾病
    • 免疫疾病
    • 再生醫學
    • 其他
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 研究機構
    • 生物樣本庫
    • 其他
  • 市場規模及預測：依製程分類
    • 收藏
    • 流程
    • 保持
    • 其他
  • 市場規模及預測：依市場細分
    • 公營銀行
    • 私人銀行
    • 混合銀行
    • 其他
  • 市場規模及預測：按解決方案分類
    • 治療方案
    • 研究解決方案
    • 其他

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲國家
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 其他亞太國家
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲國家

第6章 市場策略

  • 供需差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 監管概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 大公司的策略

第8章：公司簡介

  • Cord Blood Registry
  • ViaCord
  • Cryo-Cell International
  • China Cord Blood Corporation
  • CBR Systems
  • LifeCell International
  • Cryo-Save
  • Smart Cells International
  • StemCyte
  • Americord Registry
  • Cells4Life
  • Future Health Biobank
  • Global Cord Blood Corporation
  • Cordlife Group
  • Biovault Family
  • Stemlife Berhad
  • FamiCord Group
  • New England Cord Blood Bank
  • AlphaCord
  • Cell Care

第9章 關於我們

簡介目錄
Product Code: GIS33217

The global Stem Cell Umbilical Cord Blood Market is projected to grow from $4.2 billion in 2025 to $7.8 billion by 2035, at a compound annual growth rate (CAGR) of 6.2%. Growth is driven by increasing demand for regenerative medicine, advancements in stem cell research, and rising awareness of cord blood banking benefits. The Stem Cell Umbilical Cord Blood Market is characterized by a moderately consolidated structure, with the top segments being private cord blood banking, which holds approximately 60% of the market share, and public cord blood banking at around 40%. Key applications include regenerative medicine, hematopoietic stem cell transplantation, and genetic disease treatment. The market sees a substantial volume of cord blood units being stored annually, driven by increasing awareness and advancements in therapeutic applications.

The competitive landscape features a mix of global and regional players, with significant contributions from companies like Cord Blood Registry and ViaCord. The degree of innovation is high, particularly in the development of novel storage and processing techniques. Mergers and acquisitions, as well as strategic partnerships, are prevalent as companies seek to expand their service offerings and geographic reach. Recent trends indicate a focus on enhancing technological capabilities and expanding biorepository networks to strengthen market positions.

Market Segmentation
TypeAllogeneic, Autologous, Others
ProductCord Blood Units, Cord Tissue Units, Others
ServicesCollection and Transportation, Processing, Storage, Others
TechnologyCryopreservation, Cell Expansion, Cell Separation, Others
ApplicationCancer Treatment, Blood Disorders, Metabolic Disorders, Immune Disorders, Regenerative Medicine, Others
ProcessCollection, Processing, Storage, Others
DeploymentPublic Banking, Private Banking, Hybrid Banking, Others
End UserHospitals, Research Institutes, Biobanks, Others
SolutionsTherapeutic Solutions, Research Solutions, Others

The Type segment in the Stem Cell Umbilical Cord Blood Market is primarily driven by the dominance of allogeneic and autologous stem cell therapies. Allogeneic stem cell therapies, which involve the use of donor cells, are particularly prevalent due to their applicability in treating a wide range of hematological disorders. Autologous therapies, using the patient's own cells, are gaining traction for their reduced risk of immune rejection. The increasing prevalence of genetic disorders and advancements in personalized medicine are key drivers of demand in this segment.

The Technology segment is characterized by the prominence of cryopreservation and cell expansion technologies. Cryopreservation remains the cornerstone technology, ensuring the long-term viability of stem cells for future therapeutic use. Cell expansion technologies are gaining importance as they enable the production of a sufficient quantity of cells for treatment. Innovations in bioreactor designs and automation are enhancing the efficiency and scalability of these technologies, supporting the growing demand for regenerative medicine applications.

In the Application segment, the treatment of blood disorders and cancers dominates the market, driven by the high success rates of stem cell transplants in these areas. The use of umbilical cord blood stem cells in treating leukemia, lymphoma, and sickle cell anemia is well-established, contributing to the segment's growth. Emerging applications in regenerative medicine, such as in neurology and cardiology, are expanding the market's scope, supported by ongoing clinical trials and research initiatives.

The End User segment is led by hospitals and specialty clinics, which are the primary settings for stem cell transplants and therapies. These institutions benefit from established infrastructure and expertise in handling complex procedures. Cord blood banks also play a crucial role, providing storage and preservation services that support both clinical and research activities. The increasing collaboration between hospitals and research institutions is fostering innovation and expanding the availability of advanced stem cell therapies.

The Component segment focuses on the products and services essential for the storage and processing of umbilical cord blood. Storage services, particularly private banking, are in high demand as parents opt to preserve their child's cord blood for potential future use. Processing services are critical for ensuring the quality and viability of stored stem cells. The integration of advanced IT solutions and automated processing systems is enhancing operational efficiency and reliability, driving growth in this segment.

Geographical Overview

North America: The North American stem cell umbilical cord blood market is highly mature, driven by advanced healthcare infrastructure and significant R&D investments. The United States is a key player, with demand fueled by the biotechnology and regenerative medicine sectors. Canada also contributes to market growth through supportive government policies and increasing public awareness.

Europe: Europe exhibits moderate market maturity, with strong demand from the healthcare and pharmaceutical industries. The United Kingdom and Germany are notable countries, benefiting from robust healthcare systems and ongoing research initiatives. Regulatory frameworks in the EU also support market expansion.

Asia-Pacific: The Asia-Pacific region is experiencing rapid growth, with increasing market maturity driven by expanding healthcare access and rising awareness. China and Japan are leading countries, with substantial investments in biotechnology and regenerative medicine. Government initiatives to promote healthcare advancements further bolster market demand.

Latin America: The Latin American market is in the early stages of development, with growing interest from the healthcare sector. Brazil and Mexico are notable markets, supported by improving healthcare infrastructure and increasing public awareness of stem cell therapies. Economic challenges, however, may impact growth rates.

Middle East & Africa: The Middle East & Africa region is nascent, with market growth primarily driven by the healthcare and biotechnology sectors. The United Arab Emirates and South Africa are key countries, benefiting from investments in healthcare infrastructure and government support for medical research. However, market expansion is constrained by limited resources and awareness.

Key Trends and Drivers

Trend 1 Title: Technological Advancements in Stem Cell Processing

The Stem Cell Umbilical Cord Blood Market is experiencing rapid growth due to technological advancements in stem cell processing and storage. Innovations such as automated processing systems and cryopreservation techniques have enhanced the efficiency and viability of stem cell banking. These technologies ensure higher cell recovery rates and better preservation of cell potency, making umbilical cord blood a more reliable source for regenerative medicine applications. As a result, these advancements are driving increased adoption of umbilical cord blood banking services globally.

Trend 2 Title: Regulatory Support and Standardization

Regulatory bodies worldwide are increasingly recognizing the potential of stem cell therapies, leading to more supportive frameworks and standardization in the umbilical cord blood market. The establishment of guidelines for collection, processing, and storage by organizations such as the FDA and EMA is fostering trust and encouraging investment in this sector. Standardization ensures quality and safety, which is crucial for gaining public and professional acceptance, thereby driving market growth.

Trend 3 Title: Growing Awareness and Acceptance

There is a growing awareness among expectant parents and healthcare providers about the benefits of umbilical cord blood banking. Educational campaigns and increased media coverage are highlighting its potential in treating various diseases, including leukemia and genetic disorders. This heightened awareness is leading to increased enrollment in cord blood banking programs, as more families consider it a valuable biological insurance policy for future medical needs.

Trend 4 Title: Expansion of Therapeutic Applications

The expansion of therapeutic applications for umbilical cord blood is a significant growth driver in the market. Research and clinical trials are continually uncovering new uses for stem cells in treating a broader range of conditions, including autoimmune diseases and neurological disorders. This expanding therapeutic horizon is attracting investment and interest from pharmaceutical companies, further propelling market growth and innovation.

Trend 5 Title: Strategic Collaborations and Partnerships

Strategic collaborations and partnerships between cord blood banks, research institutions, and biotechnology firms are fostering innovation and market expansion. These alliances are facilitating the sharing of knowledge, resources, and technology, which accelerates the development of new therapies and improves service offerings. Such collaborations are crucial for overcoming challenges related to cost, scalability, and regulatory compliance, ultimately driving the growth of the Stem Cell Umbilical Cord Blood Market.

Research Scope

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Process
  • 2.8 Key Market Highlights by Deployment
  • 2.9 Key Market Highlights by Solutions

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Allogeneic
    • 4.1.2 Autologous
    • 4.1.3 Others
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Cord Blood Units
    • 4.2.2 Cord Tissue Units
    • 4.2.3 Others
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Collection and Transportation
    • 4.3.2 Processing
    • 4.3.3 Storage
    • 4.3.4 Others
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Cryopreservation
    • 4.4.2 Cell Expansion
    • 4.4.3 Cell Separation
    • 4.4.4 Others
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Cancer Treatment
    • 4.5.2 Blood Disorders
    • 4.5.3 Metabolic Disorders
    • 4.5.4 Immune Disorders
    • 4.5.5 Regenerative Medicine
    • 4.5.6 Others
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Hospitals
    • 4.6.2 Research Institutes
    • 4.6.3 Biobanks
    • 4.6.4 Others
  • 4.7 Market Size & Forecast by Process (2020-2035)
    • 4.7.1 Collection
    • 4.7.2 Processing
    • 4.7.3 Storage
    • 4.7.4 Others
  • 4.8 Market Size & Forecast by Deployment (2020-2035)
    • 4.8.1 Public Banking
    • 4.8.2 Private Banking
    • 4.8.3 Hybrid Banking
    • 4.8.4 Others
  • 4.9 Market Size & Forecast by Solutions (2020-2035)
    • 4.9.1 Therapeutic Solutions
    • 4.9.2 Research Solutions
    • 4.9.3 Others

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Process
      • 5.2.1.8 Deployment
      • 5.2.1.9 Solutions
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Process
      • 5.2.2.8 Deployment
      • 5.2.2.9 Solutions
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Process
      • 5.2.3.8 Deployment
      • 5.2.3.9 Solutions
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Process
      • 5.3.1.8 Deployment
      • 5.3.1.9 Solutions
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Process
      • 5.3.2.8 Deployment
      • 5.3.2.9 Solutions
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Process
      • 5.3.3.8 Deployment
      • 5.3.3.9 Solutions
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Process
      • 5.4.1.8 Deployment
      • 5.4.1.9 Solutions
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Process
      • 5.4.2.8 Deployment
      • 5.4.2.9 Solutions
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Process
      • 5.4.3.8 Deployment
      • 5.4.3.9 Solutions
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Process
      • 5.4.4.8 Deployment
      • 5.4.4.9 Solutions
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Process
      • 5.4.5.8 Deployment
      • 5.4.5.9 Solutions
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Process
      • 5.4.6.8 Deployment
      • 5.4.6.9 Solutions
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Process
      • 5.4.7.8 Deployment
      • 5.4.7.9 Solutions
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Process
      • 5.5.1.8 Deployment
      • 5.5.1.9 Solutions
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Process
      • 5.5.2.8 Deployment
      • 5.5.2.9 Solutions
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Process
      • 5.5.3.8 Deployment
      • 5.5.3.9 Solutions
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Process
      • 5.5.4.8 Deployment
      • 5.5.4.9 Solutions
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Process
      • 5.5.5.8 Deployment
      • 5.5.5.9 Solutions
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Process
      • 5.5.6.8 Deployment
      • 5.5.6.9 Solutions
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Process
      • 5.6.1.8 Deployment
      • 5.6.1.9 Solutions
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Process
      • 5.6.2.8 Deployment
      • 5.6.2.9 Solutions
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Process
      • 5.6.3.8 Deployment
      • 5.6.3.9 Solutions
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Process
      • 5.6.4.8 Deployment
      • 5.6.4.9 Solutions
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Process
      • 5.6.5.8 Deployment
      • 5.6.5.9 Solutions

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Cord Blood Registry
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 ViaCord
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Cryo-Cell International
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 China Cord Blood Corporation
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 CBR Systems
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 LifeCell International
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Cryo-Save
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Smart Cells International
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 StemCyte
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Americord Registry
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Cells4Life
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Future Health Biobank
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Global Cord Blood Corporation
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Cordlife Group
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Biovault Family
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Stemlife Berhad
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 FamiCord Group
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 New England Cord Blood Bank
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 AlphaCord
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Cell Care
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us